Breast Cancer Segment to Lead Doxorubicin Market During 2022-2028

According to our latest study, titled "Doxorubicin Market Forecast to 2028 - COVID-19 Impact and Global Analysis - By Drug Formulation, Distribution Channel, and Geography," the market is expected to reach US$ 1,983.40 million in 2028 from US$ 1,390.64 million in 2022. It is estimated to grow at a CAGR of 6.1% during 2022-2028. The report highlights the key factors driving the global doxorubicin market growth and prominent players with their developments in the doxorubicin market.

Doxorubicin is a cytotoxic anthracycline antibiotic, typically used in combination with other chemotherapeutic agents to treat various carcinomas, including breast cancer, Hodgkin's, and non-Hodgkin's lymphoma, leukemia, gastric carcinoma, sarcomas, and thyroid carcinoma. The growth of the global doxorubicin market is primarily attributed to the increasing prevalence of cancer and the increasing preference for chemotherapy. According to the World Health Organization (WHO), cancer was the first leading cause of death in people below 70 years in 183 countries and the fourth major cause of death among the population of all ages in 123 countries worldwide in 2019. The increasing prevalence of cancer has burdened healthcare systems worldwide, bolstering the demand for chemotherapy.

However, the potential side effects of doxorubicin are expected to restrict the market growth during the forecast period.

Based on application, the global doxorubicin market is segmented into lung cancer, sarcoma, breast cancer, multiple myeloma, ovarian cancer, kidney cancer, leukemia, liver cancer, and others. In 2022, the breast cancer segment will likely hold the market's largest share. Further, the kidney cancer segment is expected to witness growth in demand at the fastest CAGR from 2022 to 2028. The growing incidences of kidney cancer globally have led to the rise in the demand for doxorubicin. For instance, according to WHO, approximately 431,288 new cases of kidney cancer were registered, along with 179,368 deaths globally in 2020.

Based on drug formulation, the global doxorubicin market is segmented into lyophilized powder and doxorubicin injection. In 2022, the lyophilized powder will likely account for a larger share of the global market. Moreover, the same segment is anticipated to register the highest CAGR in the market from 2022 to 2028. The major driving factor for the growth of the lyophilized powder segment is its storage stability, which maintains its solid state at room temperature. Lyophilized powder can be used as a chemotherapy drug against various cancer types, such as lymphoma, carcinoma, and various sarcomas. Doxil is the first successful liposome-based product for treating patients with ovarian cancer and AIDs-related Kaposi's sarcoma, which Johnson and Johnson manufactured. Likewise, Elan Pharmaceuticals developed a liposomal product Myocet, for the delivery of doxorubicin, which was approved by the US Food and Drug Administration (US FDA) in 2000 for the treatment of metastatic breast cancer. Various other products under this drug formulation segment include ThermoDox by Celsion and Adriblastina by Pfizer.

Accord Healthcare, Cipla Inc., Dr. Reddy, Cadila Pharmaceuticals, Meiji Seika Pharma Co., Janssen Pharmaceutical (Johnson & Johnson Services, Inc.), Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., and Baxter International Inc. are a few key players operating in the global doxorubicin market. In August 2021, Pfizer acquired Trillium Therapeutics Inc. With next-generation, experimental immuno-therapeutics for hematological malignancies, the proposed purchase expands Pfizer's category leadership in oncology. In September 2020, Zydus Cadila has received final approval from the USFDA to market Doxorubicin Hydrochloride Liposome Injection This is the group's first approval for a complex injectable that has been developed in-house and will be manufactured at the group's facility located in SEZ.

The report segments the global doxorubicin market as follows:

Based on Drug Formulation, the global doxorubicin market is fragmented into lyophilized powder and doxorubicin injection. Based on the Application, the global doxorubicin market is segmented into Lung Cancer, Sarcoma, Breast Cancer, Multiple Myeloma, Ovarian Cancer, Kidney Cancer, Leukemia, Liver Cancer, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on Geography, the market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com